Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 04:00 AM ET Company ParticipantsCarla Burigatto - EVP of Communications and Corporate AffairsHelen Giza - CEOMaria Rugamer - JournalistMartin Fischer - CFOPatricia Weiss - Senior CorrespondentNone - Company RepresentativeCarla BurigattoGood morning, and welcome to Fresenius Medical Care AG's annual press conference. My name is Carla Burigato, Executive Vice President, Communications and Corporate Affairs. I'm delighted to welcome you ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 04:00 AM ET Company ParticipantsBritta Becks - Reporter and CorrespondentCarla Burigatto - EVP of Communications and Corporate AffairsHelen Giza - CEOMarcel Jan Dinkel - News ReporterMaria Rugamer - JournalistMartin Fischer - CFOPatricia Weiss - Senior CorrespondentSonja Wind - News ReporterCarla BurigattoGood morning, and welcome to Fresenius Medical Care AG's Annual Press Conference. My name is Carla Burigatto, Executive Vice Presid ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 04:00 AM ET Speaker0Good morning, and welcome to Fresenius Medical Care AG's annual press conference. My name is Carla Burigato, Executive Vice President, Communications and Corporate Affairs. I'm delighted to welcome you today and appreciate all the journalists joining via live stream. Today's press conference is virtual and being streamed publicly as a webcast in both English and German. You can select your preferred language at the ...

Fresenius Medical Care AG Investor Presentation FY 2025 Safe harbor statement: In this Safe harbor statement, "the Company" and "Fresenius Medical Care" refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conversion of legal form. This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as ...

This photograph shows European countries' flags waving in front of the European Parliament building in Strasbourg, eastern France, on June 6, 2024. (Photo by SEBASTIEN BOZON / AFP) (Photo by SEBASTIEN BOZON/AFP via Getty Images)LONDON — European stocks are expected to open flat to higher on Tuesday as investors assess the new global trading landscape after U.S. President Donald Trump's latest tariff move.The U.K.'s FTSE index is seen opening unchanged, Germany's DAX and France's CAC 40 up around 0.25%, resp ...

Core Insights - Fresenius Medical Care reported a significant increase in fourth-quarter operating income, rising 44% to 705 million euros ($830 million), surpassing analysts' expectations of 633 million euros [1][3] - The company's revenue for the fourth quarter was 5.07 billion euros, aligning with market expectations, indicating effective efficiency measures that countered U.S. labor cost inflation and currency pressures [3] Group 1 - The increase in operating income was attributed to accelerating cost savings and favorable reimbursement effects [1] - CEO Helen Giza emphasized the company's commitment to improving profitability while investing in future growth and addressing regulatory challenges, marking the next phase of the "FME Reignite" strategy [2] - The company is undergoing a major overhaul focused on margin recovery, cost discipline, and portfolio simplification following its deconsolidation from former parent Fresenius in 2023 [2]

Core Insights - The U.S. medical instrument and medtech sector is stabilizing as it enters 2026, with normalized procedure volumes post-pandemic and a focus on productivity and cost management [1][3] - Companies that can demonstrate operational improvements and earnings visibility are favored in the current investment environment, despite modest top-line growth [1][6] U.S. Macro Trends - Medtech equities are influenced by U.S. macroeconomic factors, particularly the Federal Reserve's interest rate policy, which is currently targeted between 3.5% and 3.75% [3] - Elevated labor and materials inflation rates have moderated, impacting margins more than demand, as companies align pricing and productivity with cost structures [4] Hospital Dynamics - U.S. hospitals are managing tight capital budgets while maintaining steady procedure volumes, benefiting companies with strong service and consumables revenue rather than those reliant on large equipment sales [5] - Staffing shortages are driving hospitals towards automation and efficiency, creating opportunities for device manufacturers offering productivity-enhancing solutions [5] Investment Opportunities in Undervalued Stocks - Undervalued medtech stocks may outperform through earnings recovery and multiple re-rating, as historical periods of uncertainty often compress valuations [6][7] - "Undervalued" stocks are defined as those trading below their historical valuation ranges, with potential for earnings growth through operational leverage and cost-reduction initiatives [7] Company-Specific Insights Fresenius Medical Care (FMS) - FMS is experiencing margin recovery due to cost savings and pricing improvements, with a current P/S F12M of 0.55x, below its 5-year median of 0.63x [10][11] - The company reported a rise in operating margin to 11.7% for Q3 2025, supported by cost savings and disciplined execution, with an expected earnings growth of 9% in 2026 [11][13] Integra LifeSciences (IART) - IART operates in neurosurgery and surgical instruments, currently trading at a P/S F12M of 0.59x, below its 5-year median of 2.14x [14][15] - The company anticipates supply normalization and margin expansion initiatives targeting $25-$30 million in savings, with expected earnings growth of 5.5% in 2026 [15][16] STERIS (STE) - STERIS provides sterilization services and is currently trading at a P/S F12M of 4.23x, slightly above its 5-year median of 3.97x [18][19] - The company reported high-single-digit organic revenue growth and expanded EBIT margin to 23.1%, with an expected earnings growth of 8.6% in 2026 [19][21]

Group 1 - U.S. stock futures are lower, with Dow futures down approximately 100 points [1] - Glaukos Corp reported preliminary FY25 sales of $507 million, leading to a 12.1% drop in shares to $96.97 in pre-market trading [1] Group 2 - Briacell Therapeutics Corp experienced a significant decline of 53.1% to $5.12 after announcing a $30 million public offering [2] - Trip.com Group Ltd shares fell 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [2] - Pearson PLC shares decreased by 7.2% to $13.36 following a trading update for 2025 [2] - Olema Pharmaceuticals Inc shares declined 5.5% to $26.37 after a previous drop of 3% [2] - Fresenius Medical Care AG shares fell 4.8% to $21.79 [2] - Ambitions Enterprise Management Co LLC shares dropped 4.3% to $11.81 after a significant increase of 134% the previous day [2] - NovaBay Pharmaceuticals Inc shares decreased by 3.8% to $12.55 following a 3% drop on Tuesday [2] - SmartRent Inc shares fell 2.3% to $1.74 in pre-market trading [2]

Company Overview - Fresenius Medical Care is currently stronger and more resilient, with a clear strategy aimed at driving profitable growth and long-term value creation [3] - The company has embarked on its strategy, with 2026 identified as a significant transition year, focusing on setting a new standard of care in the United States through a large-scale conversion of clinics with a new therapy [3] Industry Insights - The fundamentals of the kidney care industry remain intact, largely unaffected by broader macroeconomic cycles [5] - Structural drivers such as an aging population, chronic conditions like hypertension and diabetes, and increased recognition of chronic kidney disease as a public health crisis continue to support global demand for kidney care services [5]

Summary of Fresenius Medical Care FY Conference Call Company Overview - **Company**: Fresenius Medical Care (NYSE: FMS) - **Industry**: Kidney care and dialysis services Core Points and Arguments 1. **Strategic Direction**: Fresenius Medical Care is focused on driving profitable growth and long-term value creation, with 2026 marked as a transition year for implementing a new standard of care in the U.S. through large-scale clinic conversions to a new therapy [2][12] 2. **Industry Fundamentals**: The kidney care industry fundamentals remain strong, driven by an aging population and chronic conditions like hypertension and diabetes, which support global demand for kidney replacement therapies [3] 3. **Pharmaceutical Advancements**: New drugs, particularly GLP-1s, show promise in improving cardiovascular health and reducing mortality in chronic kidney disease (CKD) patients, with a reported 23% improvement in mortality for dialysis patients using these drugs [4] 4. **Market Position**: Fresenius Medical Care is a market leader with over 290,000 patients and 3,600 clinics globally, managing over $7 billion in medical costs and holding a 40% market share in in-center hemodialysis (HD) products [5] 5. **Operational Efficiency**: The company has improved its operating margin from 7.9% in 2022 to 10.3% in 2025, supported by the FME25+ transformation program, which is expected to deliver €790 million in sustainable savings by 2025 [8] 6. **Shareholder Returns**: The 2024 dividend payment was the highest in company history, reflecting a 13% CAGR since 2022, alongside a €1 billion share buyback program initiated in 2025 [9] 7. **Debt Management**: The net leverage ratio has been reduced from 3.4 times in 2022 to 2.6 times by Q3 2025, indicating improved financial health [10] 8. **FME Reignite Strategy**: This new strategy aims to enhance core operations, drive growth and innovation, and strengthen company culture, with aspirations for mid-teen margins by 2030 [12][13] Additional Important Insights 1. **Patient Care Focus**: The company is addressing patient outflow issues by enhancing treatment adherence and reducing missed treatments, which have been exacerbated post-COVID [29][30] 2. **HDF Therapy Rollout**: The introduction of high-volume HDF therapy is expected to significantly improve patient outcomes, with a target to convert 20% of machines in clinics by 2026 [19][20] 3. **Market Dynamics**: The company is navigating challenges such as elevated mortality rates and missed treatments, while also adapting to changes in ACA subsidies that may impact patient behavior [26][35] 4. **Innovation Pipeline**: The 5008X machine rollout is a key innovation, with production capacity of 15,000 machines per year, aimed at enhancing patient care and operational efficiency [17][45] 5. **Long-term Growth Outlook**: The company anticipates robust cash flow generation, projecting operating cash flow above €2.5 billion annually through 2030, supporting its growth and shareholder return strategies [23][27] This summary encapsulates the key points discussed during the Fresenius Medical Care FY Conference, highlighting the company's strategic initiatives, market position, and outlook for future growth.